Product Images Gabapentin

This text appears to describe various symptoms and conditions related to a health issue. Some of the mentioned symptoms include a lack of coordination, viral infection, difficulty with speaking, tremor, swelling (usually of the legs and feet), feeling tired, fever, feeling drowsy, nausea and vomiting, jerky movements, difficulty with coordination, double vision, and unusual eye movement. These symptoms may suggest a range of potential health concerns, so it would be advisable to consult a medical professional for a proper evaluation and diagnosis.*

NOT AVAILABLE*

This text provides information on the risk associated with antiepileptic drugs based on different indications. The indications mentioned are epilepsy, psychiatric, and other. The table presents the number of events per 1,000 patients in both the placebo group and the group taking the drug. It also includes the relative risk and risk difference for each indication.*

TABLE 3. Adverse Reactions in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia This table provides data on the adverse reactions experienced by patients in placebo-controlled trials for postherpetic neuralgia (a type of nerve pain caused by shingles). The table compares the occurrence of these reactions in patients taking gabapentin versus those given a placebo. Some of the adverse reactions reported include: - Body as a Whole: Asthenia (weakness or fatigue), Infection, Accidental injury - Digestive System: Diarrhea, Dry mouth, Constipation, Nausea, Vomiting - Metabolic and Nutritional: Peripheral edema (swelling in the extremities), Weight gain, Hyperglycemia (high blood sugar) - Nervous System: Dizziness, Somnolence (sleepiness), Ataxia (loss of muscle coordination), Abnormal thinking, Abnormal gait, Incoordination - Respiratory System: Pharyngitis (sore throat) - Special Senses: Amblyopia (reduced vision in one or both eyes), Conjunctivitis (pink eye), Diplopia (double vision), Otitis media (ear infection) These adverse reactions were reported, and among them, blurred vision was noted.*

TABLE 4. Adverse Reactions In Pooled Placebo-Controlled Add-On Trials In Epilepsy Patients >12years of age This table provides information on the adverse reactions observed in pooled placebo-controlled add-on trials in epilepsy patients who are 12 years of age or older. The trials compared Gabapentin® to placebo. The number of patients included in each group (Gabapentin® and placebo) is listed as well as the percentage of occurrence for each adverse reaction. The adverse reactions are categorized by the body system affected. Some of the adverse reactions observed include fatigue, weight gain, back pain, peripheral edema, cardiovascular reactions such as vasodilation, digestive system issues like dyspepsia, dry mouth or throat, constipation, and dental abnormalities. Nervous system reactions include somnolence, dizziness, ataxia, nystagmus, tremor, dysarthria, amnesia, depression, abnormal thinking, and abnormal coordination. Respiratory system reactions included pharyngitis and coughing, while skin and appendage reactions included abrasion. Urogenital system reactions included impotence, and special senses reactions included diplopia and amblyopia (blurred vision). Note: The text also mentions that amblyopia was often described as blurred vision.*

This text provides information about controlled studies on the use of Gabapentin for the treatment of PHN (postherpetic neuralgia). The table lists the duration of the studies, the dosages of Gabapentin used, and the number of patients receiving Gabapentin and placebo. The first study lasted 8 weeks and used a daily dosage of 3600 mg, with 113 patients receiving Gabapentin and 116 receiving placebo. The second study lasted 7 weeks and used daily dosages of 1800 mg and 2400 mg, with 223 patients receiving Gabapentin and 111 receiving placebo. In total, there were 336 patients receiving Gabapentin and 221 receiving placebo in these studies. The Gabapentin was administered in 3 divided doses per day.*

This text seems to be a formula for calculating a variable, possibly related to medical evaluation. However, due to the poor quality, it is difficult to determine the precise meaning of the formula. Therefore, a useful description cannot be generated.*

Figure 2 shows the weekly mean pain scores observed in Study 2 for the ITT population. The baseline pain score is not available in the text.*

Not available.*

Not available*